ENO2 and teratoma: The combined analysis of cfDNA and N-glycan profiles in blood plasma achieved an AUC of 0.96, improving the detection reliability for STM-negative NSE patients and specifically identifying all pure teratoma cases within our cohort (Fig. 5).